Events and Presentations

ESMO Sarcoma and Rare Cancers Congress 2026
 Thursday, March 12, 2026
 11:30am - 11:35am CET
  • Title: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing Sarcoma
  • Oral presentation
  • Abstract number: 84MO
  • Lead author: Rashmi Chugh
  • Presenting author: Ana Sebio García
INBRX-109 in Ewing sarcoma Data Update Oral Presentation
1.3 MB
Back To Top